Inventor · disambiguated record
Ulrich Hersel
Also filed as: HERSEL ULRICH
42 granted patents·33 pending applications·428 citations·filing 2001–2024
98Inventor score
Files withASCENDIS PHARMA GROWTH DISORDERS AS25ASCENDIS PHARMA AS17HERSEL ULRICH8RAU HARALD6ASCENDIS PHARMA GMBH3
Top patents by PatentIndex Score
75 records- 0197US11154593B2CNP prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2021·Granted Oct 26, 2021·13 cites·28 claims
- 0297US10835578B2CNP prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Nov 17, 2020·21 cites·20 claims
- 0397US9056126B2Hydrogel formulationsHERSEL ULRICH·Filed 2011·Granted Jun 16, 2015·59 cites·23 claims
- 0495US12156917B2CNP prodrugs with carrier attachment at the ring moietyASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Granted Dec 3, 2024·2 cites·13 claims
- 0595US8906847B2Prodrug comprising a drug linker conjugateCLEEMANN FELIX·Filed 2009·Granted Dec 9, 2014·86 cites·37 claims
- 0693US12083182B2Controlled-release CNP agonists with increased NEP stabilityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2021·Granted Sep 10, 2024·3 cites·15 claims
- 0790US11389510B2Controlled-release CNP agonists with low initial NPR-B activityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jul 19, 2022·5 cites·6 claims
- 0890US10960053B2PEGylated recombinant human growth hormone compoundsASCENDIS PHARMA ENDOCRINOLOGY DIV A/S·Filed 2018·Granted Mar 30, 2021·5 cites·13 claims
- 0990US8377917B2Polymeric prodrug with a self-immolative linkerCOMPLEX BIOSYSTEMS GMBH·Filed 2005·Granted Feb 19, 2013·23 cites·36 claims
- 1089US11413351B2CNP prodrugs with carrier attachment at the ring moietyASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Aug 16, 2022·7 cites·17 claims
- 1189US9173953B2Prodrugs containing an aromatic amine connected by an amido bond to a linkerRAU HARALD·Filed 2010·Granted Nov 3, 2015·22 cites·20 claims
- 1289US2025127797A1Prodrug comprising a drug-linker conjugateASCENDIS PHARMA AS·Filed 2024·Application pending·0 cites
- 1389US2025127859A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 1488US12239689B2Controlled-release CNP agonists with low initial NPR-B activityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Granted Mar 4, 2025·1 cites·10 claims
- 1588US11389511B2Controlled-release CNP agonists with reduced side-effectsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jul 19, 2022·7 cites·16 claims
- 1688US11224661B2Controlled-release CNP agonists with increased NEP stabilityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Jan 18, 2022·7 cites·13 claims
- 1788US9272048B2PEGylated recombinant human growth hormone compoundsRAU HARALD·Filed 2009·Granted Mar 1, 2016·15 cites·37 claims
- 1887US9278139B2Sterilization of biodegradable hydrogelsASCENDIS PHARMA AS·Filed 2015·Granted Mar 8, 2016·7 cites·17 claims
- 1987US7968085B2Hydrogel formulationsASCENDIS PHARMA AS·Filed 2004·Granted Jun 28, 2011·37 cites·16 claims
- 2087US2025090671A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 2186US2024316153A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 2285US11311604B2Controlled-release CNP agonists with low NPR-C bindingASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2017·Granted Apr 26, 2022·6 cites·10 claims
- 2385US10980860B2Diagnosis, prevention and treatment of diseases of the jointASCENDIS PHARMA AS·Filed 2013·Granted Apr 20, 2021·11 cites·15 claims
- 2485US10098930B2PEGylated Recombinant Human Growth Hormone CompoundsASCENDIS PHARMA GROWTH DISORDERS DIV A/S·Filed 2016·Granted Oct 16, 2018·10 cites·12 claims
- 2585US9457066B2Prodrugs comprising an insulin linker conjugateSANOFI AVENTIS DEUTSCHLAND·Filed 2015·Granted Oct 4, 2016·6 cites·24 claims
- 2685US2024041897A1Prodrug comprising a drug linker conjugateASCENDIS PHARMA AS·Filed 2023·Application pending·0 cites
- 2782US8986609B2Sterilization of biodegradable hydrogelsRAU HARALD·Filed 2010·Granted Mar 24, 2015·6 cites·16 claims
- 2882US2025121074A1Cnp prodrugs with carrier attachment at the ring moietyASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 2982US2022331334A1Prodrug Comprising a Drug-Linker ConjugateASCENDIS PHARMA AS·Filed 2022·Application pending·0 cites
- 3080US9265723B2Long acting insulin compositionSPROGOE KENNETT·Filed 2010·Granted Feb 23, 2016·11 cites·50 claims
- 3179US10029015B2Hydrogel formulationsASCENDIS PHARMA AS·Filed 2015·Granted Jul 24, 2018·2 cites·22 claims
- 3279US9872864B2Sustained release composition of prostacyclinSPROGØE KENNETT·Filed 2012·Granted Jan 23, 2018·6 cites·13 claims
- 3378US9133276B2Prodrugs comprising an exendin linker conjugateCLEEMANN FELIX·Filed 2011·Granted Sep 15, 2015·6 cites·26 claims
- 3477US10729778B2Carrier-linked treprostinil prodrugsHERSEL ULRICH·Filed 2017·Granted Aug 4, 2020·1 cites·24 claims
- 3577US2022296682A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2021·Application pending·0 cites
- 3677US2025090639A1Controlled-release cnp agonists with low initial npr-b activityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 3776US7655624B2Peptide and peptide mimetic conjugates with integrin-inhibitor propertiesBIOMET DEUTSCHLAND GMBH·Filed 2001·Granted Feb 2, 2010·12 cites·12 claims
- 3876US2020046725A1Prodrug Comprising a Drug Linker ConjugateASCENDIS PHARMA AS·Filed 2019·Application pending·0 cites
- 3976US2025041431A1Controlled-release cnp agonists with increased nep stabilityASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2024·Application pending·0 cites
- 4075US9561287B2Carrier-linked treprostinil prodrugsHERSEL ULRICH·Filed 2012·Granted Feb 7, 2017·3 cites·28 claims
- 4175US8980242B2Aliphatic prodrug linkerVETTER DIRK·Filed 2006·Granted Mar 17, 2015·3 cites·50 claims
- 4273US12274737B2PEGylated recombinant human growth hormone compoundsASCENDIS PHARMA ENDOCRINOLOGY DIV A/S·Filed 2021·Granted Apr 15, 2025·0 cites·18 claims
- 4373US9913912B2Carrier-linked prostanoid prodrugsASCENDIS PHARMA AS·Filed 2013·Granted Mar 13, 2018·2 cites·21 claims
- 4473US2023116746A1Cnp prodrugsASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2022·Application pending·0 cites
- 4572US2021077584A1Cnp prodrugs with large carrier moietiesASCENDIS PHARMA GROWTH DISORDERS AS·Filed 2020·Application pending·0 cites
- 4671US9238686B2Polymeric prodrug with self-immolative linkerASCENDIS PHARMA GMBH·Filed 2013·Granted Jan 19, 2016·2 cites·28 claims
- 4768US7879588B2Protein-proteophore complexesASCENDIS PHARMA AS·Filed 2004·Granted Feb 1, 2011·19 cites·10 claims
- 4866US9138462B2Prodrugs comprising an insulin linker conjugateRAU HARALD·Filed 2010·Granted Sep 22, 2015·1 cites·27 claims
- 4966US2017100490A1Prodrug Comprising a Drug Linker ConjugateASCENDIS PHARMA AS·Filed 2016·Application pending·0 cites
- 5066US2021283264A1Polymeric Prodrugs with a Self-Immolative LinkerASCENDIS PHARMA GMBH·Filed 2021·Application pending·0 cites
Showing the top 50 of 75 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ulrich Hersel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →